Last updated on 8/1/22 | First published on 2/1/18 | Literature review current through Oct. 2024
[cite]
(2022).
"Inflammatory Ulcers ". In
(Eds.)
, WoundReference.
Available from: https://woundreference.com/app/topic?id=inflammatory-ulcers-coming-soon. Retrieved on 11/24/24.
Inflammatory ulcers refer specifically to those ulcerations in which inflammation is the primary pathologic process resulting in lesion formation; that is, when inflammation is the cause rather than the consequence of the ulcer.[1] This series on inflammatory ulcers is comprised of:
Pyoderma Gangrenosum
- Pyoderma Gangrenosum - Introduction and Assessment: Pyoderma gangrenosum is a rare but serious primary ulcerating condition of the skin that falls into the category of neutrophilic dermatoses. This topic provides a framework for assessment of patients with pyoderma gangrenosum. Includes concise abstract, clinical pathway/algorithm for use at the point-of-care, and comprehensive resources on the condition (e.g. epidemiology, risk factors, etiology, pathophysiology, history, physical examination, diagnosis, differential diagnoses, documentation and ICD-10 coding)
- Pyoderma Gangrenosum - Treatment: Currently, there is no definitive guideline or gold standard in management of pyoderma gangrenosum, as data from controlled clinical trials are scarce. This topic provides a current review on management of pyoderma gangrenosum, with a concise algorithm/pathway for use at the point-of-care
Cutaneous vasculitis
- Cutaneous Vasculitis: This topic provides an updated, summarized review on assessment and management of cutaneous vasculitis.
Cutaneous Manifestations Associated With COVID-19
Ulcerative lichen planus: Coming soon!
Ulcerative necrobiosis lipoidica: Coming soon!
Ulcerative sarcoidosis: Coming soon!
Wegener’s granulomatosis: Coming soon!
Official reprint from WoundReference® woundreference.com ©2024 Wound Reference, Inc. All Rights Reserved
Use of WoundReference is subject to the
Subscription and License Agreement.
NOTE: This is a controlled document. This document is not a substitute for proper training, experience, and exercising of professional judgment. While every effort has been made to ensure the accuracy of the contents, neither the authors nor the Wound Reference, Inc. give any guarantee as to the accuracy of the information contained in them nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omissions in the contents of the work.
REFERENCES
-
Hoffman MD. Inflammatory ulcers. Clinics in dermatology. 2007;volume 25(1):131-8.
Topic 764 Version 1.0
SUBTOPICS
This topic provides a review on the available knowledge on cutaneous manifestations associated with COVID-19, based on literature review and on data published by the international registry from the American Academy of Dermatology and International League of Dermatological Societies.
INTRODUCTIONBackgroundDefinition:Vasculitis of the skin (cutaneous vasculitis) includes several inflammatory disorders that compromise blood vessels and specifically the cutaneous vascular system (i.e. arterioles, capillaries, postcapillary venules), and lead to cutaneous changes. (Papi and Papi 2016) According to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012), cutaneous vasculitis can present in 3
Pyoderma gangrenosum is a rare but serious primary ulcerating condition of the skin that falls into the category of neutrophilic dermatoses. This topic provides a framework for assessment of patients with pyoderma gangrenosum. Includes concise abstract, clinical pathway/algorithm for use at the point-of-care, and comprehensive resources on the condition (e.g. epidemiology, risk factors, etiology, pathophysiology, history, physical examination, diagnosis, differential diagnoses, documentation and ICD-10 coding)
Pyoderma gangrenosum is a rare but serious primary ulcerating condition of the skin that falls into the category of neutrophilic dermatoses. Currently, there is no definitive guideline or gold standard in management of pyoderma gangrenosum, as data from controlled clinical trials are scarce. This topic provides an evidence-based, always current review on management of pyoderma gangrenosum, with a concise algorithm/pathway for use at the point-of-care
